Amgen Inc.

Mei-Mei Tsai

Rajendra V Deshpande

Frank J Calzone

Jeonghoon Sun

Xiaolan Zhou

Qing Chen

Huiquan Han

Li Zhang

Kenneth William Walker

Mark Leo Michaels

Hosung Min

Kevin Graham

Grant Shimamoto

Xueming Qian

Aaron George Winters

Barbara S Tipton

Francesco Galimi

Chadwick Terence King

Randal Robert Ketchem

Colin V Gegg

Colin Victor Gegg, Jr

Alice Bakker

Monica Florio

Irwin Chen

Amy N Duguay

Benjamin M Alba

Peter Coward

Shi-Yuan Meng

Susie Miki Harris

Ryan B Case

Peng Li

Seog Joon Han

Ji Lu

Steven A Moore, Jr

Aaron Avraham Nazarian

Marc W Retter

Susie M Harris

Jr Steven A Moore

This disclosure related to antagonistic dual receptor antigen-binding proteins, e.g. antibodies and methods of using the dual receptor antibodies for treatment of pathological diseases. The dual receptor antibodies may comprise an antibody to ActRII receptors and may be used to treat pathological condition. The pathological conditions can comprise muscle wasting diseases or any disease that requires stimulation of muscle growth.

Dual receptor antagonistic antigen-binding proteins and uses thereof

This disclosure relates to antagonistic dual receptor antigen-binding proteins, e.g. antibodies and methods of using the dual receptor antibodies for treatment of pathological diseases. The dual receptor antibodies may comprise an antibody to ActRII receptors and may be used to treat pathological condition. The pathological conditions can comprise muscle wasting diseases or any disease that requires stimulation of muscle growth.

This disclosure relates to CB1 receptor antigen-binding proteins, e.g. antibodies and methods of using the CB1 receptor antibodies. The CB1 receptor antibodies may comprise an antagonistic antibody to CB1 receptors and may be used to treat various health conditions. The health conditions can comprise obesity or diabetes or any disease that benefits from antagonism of the CB1 receptor.

Cannabinoid receptor-1 (CB1) monoclonal antibodies

The present invention provides compositions and methods relating to or derived from anti-IGF-1R antibodies. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-1R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions.

Compositions and methods relating to anti-IGF-1 receptor antibodies

The present application is directed to avimers and peptides and various combinations thereof in addition to methods of making and using them.

Inhibitory polypeptides specific to WNT inhibitors

Described herein are variant Fc-fragments that contain an insertion within or adjacent to a loop that bind to the neonatal Fc receptor (FcRn) with higher affinity and/or higher binding activity at pH 5-6 and approximately the same or lower affinity at a physiologic pH as compared to a control Fc-fragment, that is, little or no binding activity at a physiologic pH. Also described are variant Fc-polypeptides that comprise these variant Fc-fragments. Further described are methods of making and identifying such Fc-fragments and methods for making and using such Fc-polypeptides.

Variant Fc-polypeptides with enhanced binding to the neonatal Fc receptor

The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal.

Thrombopoietic compounds

The present invention relates to binding agents for WISE, and includes for their manufacture and use.

Wise binding agents and epitopes

The present invention provides compositions and methods relating to or derived from anti-IGF-1R antibodies. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions.

Compositions and methods relating to anti IGF-1 receptor antibodies

Growing community of inventors

Thousand Oaks, CA, United States of America

Mei-Mei Tsai